| pubmed-article:20831776 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:20831776 | lifeskim:mentions | umls-concept:C0003873 | lld:lifeskim |
| pubmed-article:20831776 | lifeskim:mentions | umls-concept:C0087111 | lld:lifeskim |
| pubmed-article:20831776 | lifeskim:mentions | umls-concept:C0393022 | lld:lifeskim |
| pubmed-article:20831776 | lifeskim:mentions | umls-concept:C0679199 | lld:lifeskim |
| pubmed-article:20831776 | lifeskim:mentions | umls-concept:C0034975 | lld:lifeskim |
| pubmed-article:20831776 | lifeskim:mentions | umls-concept:C2698650 | lld:lifeskim |
| pubmed-article:20831776 | lifeskim:mentions | umls-concept:C1314901 | lld:lifeskim |
| pubmed-article:20831776 | pubmed:issue | 5 | lld:pubmed |
| pubmed-article:20831776 | pubmed:dateCreated | 2010-11-25 | lld:pubmed |
| pubmed-article:20831776 | pubmed:abstractText | This study describes the results of the Belgian 'MabThera In Rheumatoid Arthritis (MIRA)' registry: effectiveness, safety and evaluation of the current retreatment practice on the background of the Belgian reimbursement criteria for rituximab. | lld:pubmed |
| pubmed-article:20831776 | pubmed:language | eng | lld:pubmed |
| pubmed-article:20831776 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20831776 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:20831776 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20831776 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20831776 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20831776 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:20831776 | pubmed:issn | 1478-6362 | lld:pubmed |
| pubmed-article:20831776 | pubmed:author | pubmed-author:WesthovensRen... | lld:pubmed |
| pubmed-article:20831776 | pubmed:author | pubmed-author:De... | lld:pubmed |
| pubmed-article:20831776 | pubmed:author | pubmed-author:DurezPatrickP | lld:pubmed |
| pubmed-article:20831776 | pubmed:author | pubmed-author:KaiserMarie-J... | lld:pubmed |
| pubmed-article:20831776 | pubmed:author | pubmed-author:HoffmanIlseI | lld:pubmed |
| pubmed-article:20831776 | pubmed:author | pubmed-author:Vander... | lld:pubmed |
| pubmed-article:20831776 | pubmed:author | pubmed-author:MIRA Study... | lld:pubmed |
| pubmed-article:20831776 | pubmed:issnType | Electronic | lld:pubmed |
| pubmed-article:20831776 | pubmed:volume | 12 | lld:pubmed |
| pubmed-article:20831776 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:20831776 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:20831776 | pubmed:pagination | R169 | lld:pubmed |
| pubmed-article:20831776 | pubmed:meshHeading | pubmed-meshheading:20831776... | lld:pubmed |
| pubmed-article:20831776 | pubmed:meshHeading | pubmed-meshheading:20831776... | lld:pubmed |
| pubmed-article:20831776 | pubmed:meshHeading | pubmed-meshheading:20831776... | lld:pubmed |
| pubmed-article:20831776 | pubmed:meshHeading | pubmed-meshheading:20831776... | lld:pubmed |
| pubmed-article:20831776 | pubmed:meshHeading | pubmed-meshheading:20831776... | lld:pubmed |
| pubmed-article:20831776 | pubmed:meshHeading | pubmed-meshheading:20831776... | lld:pubmed |
| pubmed-article:20831776 | pubmed:meshHeading | pubmed-meshheading:20831776... | lld:pubmed |
| pubmed-article:20831776 | pubmed:meshHeading | pubmed-meshheading:20831776... | lld:pubmed |
| pubmed-article:20831776 | pubmed:meshHeading | pubmed-meshheading:20831776... | lld:pubmed |
| pubmed-article:20831776 | pubmed:meshHeading | pubmed-meshheading:20831776... | lld:pubmed |
| pubmed-article:20831776 | pubmed:meshHeading | pubmed-meshheading:20831776... | lld:pubmed |
| pubmed-article:20831776 | pubmed:year | 2010 | lld:pubmed |
| pubmed-article:20831776 | pubmed:articleTitle | The Belgian MIRA (MabThera In Rheumatoid Arthritis) registry: clues for the optimization of rituximab treatment strategies. | lld:pubmed |
| pubmed-article:20831776 | pubmed:affiliation | Department of Rheumatology, Ghent University Hospital, De Pintelaan 185, 9000 Ghent, Belgium. Bert.VanderCruyssen@Ugent.be. | lld:pubmed |
| pubmed-article:20831776 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:20831776 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:20831776 | lld:pubmed |
